Yoshio Yamamoto

发表

Analysis of Binding Sites for the New Small-Molecule CCR5 Antagonist TAK-220 on Human CCR5

Toshiya Nishi, J. Fujisawa, Naoyuki Kanzaki, 2005, Antimicrobial Agents and Chemotherapy.

Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.

H. Oki, Kenjiro Sato, O. Uchikawa, 2014, Bioorganic & medicinal chemistry.

Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125.

J. Yano, K. Aertgeerts, K. Takeuchi, 2011, Bioorganic & medicinal chemistry.

Design of potent dipeptidyl peptidase IV (DPP-4) inhibitors by employing a strategy to form a salt bridge with Lys554.

M. Tawada, N. Suzuki, S. Tsubotani, 2017, Bioorganic & medicinal chemistry letters.

Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.

M. Sasaki, J. Yano, K. Aertgeerts, 2011, Bioorganic & medicinal chemistry.

Chemical Transformation of Terpenoids. VI. Syntheses of Chiral Segments, Key Building-Blocks for the Left Half of Taxane-Type Diterpenoids

I. Kitagawa, H. Fujioka, Yoshio Yamamoto, 1984 .

Successive methyl migrations occurring in the acid treatment of 1-epoxyethyl-1,2,2-trimethyl-cyclopentane derivative

T. Hakoshima, K. Kitamura, I. Kitagawa, 1980 .

Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.

H. Oki, Kenjiro Sato, O. Uchikawa, 2014, Journal of medicinal chemistry.

Characterization of the CYP3A4 active site by homology modeling.

Toshimasa Tanaka, Teruaki Okuda, Yoshio Yamamoto, 2004, Chemical & pharmaceutical bulletin.

SYNTHESIS OF A CHIRAL 1,1,3-TRIMETHYLCYCLOHEXANE DERIVATIVE FROM d-CAMPHOR: A POTENT KEY BUILDING BLOCK FOR ENT-TAXANE-TYPE DITERPENOIDS

I. Kitagawa, H. Fujioka, A. Takagi, 1980 .

Absolute Stereostructure of Furanogermenone, a Biologically Active Sesquiterpene from Zedoariae Rhizoma

I. Kitagawa, I. Miura, Yoshio Yamamoto, 1982 .

Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.

J. Yano, K. Aertgeerts, K. Takeuchi, 2011, Bioorganic & medicinal chemistry.

Discovery of a 3-pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor.

J. Yano, K. Aertgeerts, K. Takeuchi, 2011, Journal of medicinal chemistry.

Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors.

M. Yoshikawa, T. Kawamoto, K. Okada, 2012, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.

Toshimasa Tanaka, Masami Suzuki, M. Harada, 2011, Journal of medicinal chemistry.

Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.

H. Oki, Kenjiro Sato, A. Kaieda, 2017, Journal of medicinal chemistry.

Propensities of polar and aromatic amino acids in noncanonical interactions: nonbonded contacts analysis of protein-ligand complexes in crystal structures.

Yoshihisa Inoue, Y. Inoue, Y. Imai, 2007, Journal of medicinal chemistry.

Corrigendum to “Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554” [Bioorg. Med. Chem. 19 (2011) 4482–4498]

J. Yano, K. Aertgeerts, K. Takeuchi, 2011 .

Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.

H. Oki, Kenjiro Sato, O. Uchikawa, 2014, Bioorganic & medicinal chemistry.

Discovery of a 3-pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor.

J. Yano, K. Aertgeerts, K. Takeuchi, 2011, Journal of medicinal chemistry.